Sin conexión a internet: se muestra la versión guardada de la página.

AIM ImmunoTech In…

USUSD
← Al Screener

AIM ImmunoTech Inc (LSE:0A4Y) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
aimimmuno.com
Relaciones con los Inversores
aimimmuno.com/investors/
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sede Central
OCALA, United States
Consejero Delegado
Thomas K. Equels
Empleados
19
Acciones en Circulación
30.44 M a 2026-08-07
Capital Flotante
27.64 M
Capitalización Bursátil
7.18 M USD
Insiders
0.51%
Inversores Institucionales
2.88%
Industria (SIC)
Biological Products, (No Diagnostic Substances)
FCF
—
Deuda
3.62 M USD
caja neta
Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
NAV
0.27 USD
Fecha del Balance30.06.2026
Activos12.7 M USD
− Pasivos4.99 M USD
= NAV (patrimonio de los accionistas de la empresa)7.74 M USD
− Activos Intangibles1.71 M USD
= NAV Tangible6.03 M USD
Acciones28 990 073
NAV por Acción0.27 USD
NAV Tangible por Acción0.21 USD
Historial del NAV
Fecha del BalanceNAVNAV por Acción
30.06.20267.74 M USD0.27 USD
31.03.20262.13 M USD0.26 USD
31.12.2025−9.78 M USD−3.19 USD
30.09.2025−6.08 M USD−2.20 USD
30.06.2025−6.55 M USD−8.57 USD
31.03.2025−3.86 M USD−0.05 USD
31.12.2024−1.32 M USD−2.02 USD
11.12.20246.00 M USD0.20 USD
Descripción

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksAIM principalUSD0.1618 -4.77%acciones ordinarias
LSE London Stock Exchange0A4Y IOBGBP—acciones ordinarias

Precio en 3 Meses

día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
KELLNER TED D (Director)≈4.88%3.72 M2025-04-11
Jane Street Group, LLC1.06%807 8852026-06-30
MITCHELL WILLIAM M (Dire…≈0.69%522 1032025-04-11
RODINO PETER W III (Chie…≈0.53%401 7622025-04-04
APPELROUTH STEWART L. (D…≈0.51%388 7292024-12-31
BRYAN NANCY K (Director)≈0.38%291 8822025-03-14
Virtu Financial LLC0.16%124 2692026-06-30
EQUELS THOMAS K (Officer…≈0.13%102 8222026-09-16
Morgan Stanley0.07%50 8642026-06-30
Geode Capital Management…0.06%46 0032026-06-30
Fidelity Concord Street…0.06%44 0842026-07-31
Goldman Sachs Group Inc0.04%32 4442026-06-30
UBS Group AG0.04%28 9312026-06-30
CHEMEROW DAVID I (Direct…≈0.04%28 4412026-03-12
Susquehanna Internationa…0.03%21 8592026-06-30
Vanguard Fiduciary Trust…0.02%17 5192026-06-30
Ground Swell Capital, LL…0.02%12 2222026-06-30
Tower Research Capital L…0.01%4 6682026-06-30
Fidelity Concord Street…0%6822026-07-31